{"product_id":"cjc-1295-with-dac-10mg-vial","title":"CJC-1295 with DAC 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                      \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"51\" data-end=\"673\"\u003e\u003cstrong\u003eCJC-1295\u003c\/strong\u003e with \u003cstrong data-start=\"98\" data-end=\"129\"\u003eDAC (Drug Affinity Complex)\u003c\/strong\u003e is a stabilized \u003cstrong data-start=\"146\" data-end=\"196\"\u003egrowth-hormone–releasing hormone (GHRH) analog\u003c\/strong\u003eengineered to \u003cstrong data-start=\"211\" data-end=\"250\"\u003ecovalently bind circulating albumin\u003c\/strong\u003e via its DAC moiety. This albumin conjugation dramatically \u003cstrong data-start=\"309\" data-end=\"339\"\u003eextends systemic residence\u003c\/strong\u003e and sustains \u003cstrong data-start=\"353\" data-end=\"390\"\u003ephysiologic, pulsatile GH release\u003c\/strong\u003e with downstream \u003cstrong data-start=\"407\" data-end=\"426\"\u003eIGF-1 elevation\u003c\/strong\u003e. In contrast to daily GHRH analogs (e.g., sermorelin) or short-acting “CJC without DAC” (Mod-GRF 1-29), DAC-conjugated CJC enables \u003cstrong data-start=\"558\" data-end=\"620\"\u003einfrequent injections (weekly to twice-monthly in studies)\u003c\/strong\u003e. It is \u003cstrong data-start=\"628\" data-end=\"652\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e for therapeutic use.\u003c\/p\u003e\n\u003chr data-start=\"675\" data-end=\"678\"\u003e\n\u003ch3 data-start=\"680\" data-end=\"748\"\u003eAdditional Benefits of CJC-1295 with DAC Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"750\" data-end=\"2962\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"750\" data-end=\"778\"\u003e\n\u003ctr data-start=\"750\" data-end=\"778\"\u003e\n\u003cth data-start=\"750\" data-end=\"760\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"760\" data-end=\"778\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"789\" data-end=\"2962\"\u003e\n\u003ctr data-start=\"789\" data-end=\"1110\"\u003e\n\u003ctd data-start=\"789\" data-end=\"832\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"791\" data-end=\"831\"\u003e1 Long-acting physiologic GH support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"832\" data-end=\"1110\"\u003eSingle injections \u003cstrong data-start=\"852\" data-end=\"882\"\u003eamplify GH pulse amplitude\u003c\/strong\u003e and \u003cstrong data-start=\"887\" data-end=\"902\"\u003eraise IGF-1\u003c\/strong\u003e for \u003cstrong data-start=\"907\" data-end=\"921\"\u003e~1–2 weeks\u003c\/strong\u003e, preserving hypothalamic feedback (somatostatin\/IGF-1) rather than delivering non-physiologic GH exposure. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Endocrine Reviews\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1111\" data-end=\"1394\"\u003e\n\u003ctd data-start=\"1111\" data-end=\"1162\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1113\" data-end=\"1161\"\u003e2 Adherence advantage vs daily secretagogues\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1162\" data-end=\"1394\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"1164\" data-end=\"1184\"\u003eWeekly\/bi-weekly\u003c\/strong\u003e regimens improve \u003cstrong data-start=\"1202\" data-end=\"1227\"\u003etreatment convenience\u003c\/strong\u003e and may enhance persistence compared with nightly GHRH or multiple daily secretagogue dosing. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Endocrinology; Patient Preference and Adherence\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1395\" data-end=\"1619\"\u003e\n\u003ctd data-start=\"1395\" data-end=\"1428\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1397\" data-end=\"1427\"\u003e3 Body-composition signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1428\" data-end=\"1619\" data-col-size=\"xl\"\u003eExploratory studies report \u003cstrong data-start=\"1457\" data-end=\"1493\"\u003ereductions in visceral adiposity\u003c\/strong\u003e with \u003cstrong data-start=\"1499\" data-end=\"1551\"\u003emaintenance or slight increases in fat-free mass\u003c\/strong\u003e, consistent with GH\/IGF-1 physiology. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Obesity; JCEM\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1620\" data-end=\"1856\"\u003e\n\u003ctd data-start=\"1620\" data-end=\"1658\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1622\" data-end=\"1657\"\u003e4 Lipids \u0026amp; inflammatory markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1658\" data-end=\"1856\" data-col-size=\"xl\"\u003eResponders show \u003cstrong data-start=\"1676\" data-end=\"1699\"\u003elower triglycerides\u003c\/strong\u003e and \u003cstrong data-start=\"1704\" data-end=\"1711\"\u003eCRP\u003c\/strong\u003e with \u003cstrong data-start=\"1717\" data-end=\"1742\"\u003eadiponectin increases\u003c\/strong\u003e, aligning with improved cardiometabolic risk profiles. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Lipidology; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1857\" data-end=\"2072\"\u003e\n\u003ctd data-start=\"1857\" data-end=\"1884\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1859\" data-end=\"1883\"\u003e5 Sleep architecture\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1884\" data-end=\"2072\" data-col-size=\"xl\"\u003eBedtime administration \u003cstrong data-start=\"1909\" data-end=\"1943\"\u003eaugments slow-wave sleep (SWS)\u003c\/strong\u003e in midlife adults with blunted nocturnal GH secretion; effects track with IGF-1 rises. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2073\" data-end=\"2265\"\u003e\n\u003ctd data-start=\"2073\" data-end=\"2095\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2075\" data-end=\"2094\"\u003e6 Bone turnover\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2095\" data-end=\"2265\" data-col-size=\"xl\"\u003eShort-term increases in \u003cstrong data-start=\"2121\" data-end=\"2167\"\u003ebone-formation markers (P1NP, osteocalcin)\u003c\/strong\u003e via GH→IGF-1 routes; fracture outcomes untested. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; Osteoporosis International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2266\" data-end=\"2503\"\u003e\n\u003ctd data-start=\"2266\" data-end=\"2303\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2268\" data-end=\"2302\"\u003e7 Hepatic steatosis hypothesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2303\" data-end=\"2503\" data-col-size=\"xl\"\u003eBy reducing visceral fat and modulating hepatic lipid flux, programs explore \u003cstrong data-start=\"2382\" data-end=\"2407\"\u003eMRI-PDFF improvements\u003c\/strong\u003e in NAFLD phenotypes; robust trials are pending. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology; Liver International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2504\" data-end=\"2717\"\u003e\n\u003ctd data-start=\"2504\" data-end=\"2539\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2506\" data-end=\"2538\"\u003e8 Synergy with GHSR agonists\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2539\" data-end=\"2717\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2541\" data-end=\"2564\"\u003eAdditive GH release\u003c\/strong\u003e when combined with ghrelin-mimetics (e.g., GHRP-2, hexarelin) due to \u003cstrong data-start=\"2634\" data-end=\"2656\"\u003edistinct receptors\u003c\/strong\u003e (GHRHR vs GHSR-1a). \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCEM; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2718\" data-end=\"2962\"\u003e\n\u003ctd data-start=\"2718\" data-end=\"2750\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2720\" data-end=\"2749\"\u003e9 Quality-of-life domains\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2750\" data-end=\"2962\" data-col-size=\"xl\"\u003eParticipants often note \u003cstrong data-start=\"2776\" data-end=\"2812\"\u003eenergy, recovery, and body-image\u003c\/strong\u003e improvements paralleling endocrine changes—patient-reported outcomes remain exploratory. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Endocrine Practice; Quality of Life Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2964\" data-end=\"2967\"\u003e\n\u003ch2 data-start=\"2969\" data-end=\"3004\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3006\" data-end=\"3041\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-start=\"3042\" data-end=\"3334\"\u003eCJC-1295 binds \u003cstrong data-start=\"3057\" data-end=\"3083\"\u003eGHRH receptors (GHRHR)\u003c\/strong\u003e on pituitary somatotrophs → \u003cstrong data-start=\"3112\" data-end=\"3150\"\u003eGs–adenylate cyclase–cAMP–PKA–CREB\u003c\/strong\u003e→ \u003cstrong data-start=\"3153\" data-end=\"3176\"\u003eGH pulse generation\u003c\/strong\u003e. Physiologic feedback via \u003cstrong data-start=\"3203\" data-end=\"3225\"\u003esomatostatin\/IGF-1\u003c\/strong\u003e remains intact. DAC-mediated albumin coupling \u003cstrong data-start=\"3272\" data-end=\"3302\"\u003eprolongs receptor exposure\u003c\/strong\u003e without continuous GH infusion.\u003c\/p\u003e\n\u003ch3 data-start=\"3336\" data-end=\"3363\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3365\" data-end=\"3742\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3365\" data-end=\"3407\"\u003e\n\u003ctr data-start=\"3365\" data-end=\"3407\"\u003e\n\u003cth data-start=\"3365\" data-end=\"3375\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3375\" data-end=\"3396\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3396\" data-end=\"3407\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3422\" data-end=\"3742\"\u003e\n\u003ctr data-start=\"3422\" data-end=\"3516\"\u003e\n\u003ctd data-start=\"3422\" data-end=\"3442\" data-col-size=\"sm\"\u003eGH→GHR–JAK2–STAT5\u003c\/td\u003e\n\u003ctd data-start=\"3442\" data-end=\"3490\" data-col-size=\"md\"\u003e↑ \u003cstrong data-start=\"3446\" data-end=\"3455\"\u003eIGF-1\u003c\/strong\u003e, ↑ lipolysis, ↑ protein synthesis\u003c\/td\u003e\n\u003ctd data-start=\"3490\" data-end=\"3516\" data-col-size=\"sm\"\u003eLiver, adipose, muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3517\" data-end=\"3593\"\u003e\n\u003ctd data-start=\"3517\" data-end=\"3541\" data-col-size=\"sm\"\u003ePI3K–Akt–mTOR (IGF-1)\u003c\/td\u003e\n\u003ctd data-start=\"3541\" data-end=\"3574\" data-col-size=\"md\"\u003e↑ translation, ↑ fat-free mass\u003c\/td\u003e\n\u003ctd data-start=\"3574\" data-end=\"3593\" data-col-size=\"sm\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3594\" data-end=\"3674\"\u003e\n\u003ctd data-start=\"3594\" data-end=\"3617\" data-col-size=\"sm\"\u003eAMPK\/PPAR cross-talk\u003c\/td\u003e\n\u003ctd data-start=\"3617\" data-end=\"3665\" data-col-size=\"md\"\u003e↓ de novo lipogenesis; improved VLDL handling\u003c\/td\u003e\n\u003ctd data-start=\"3665\" data-end=\"3674\" data-col-size=\"sm\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3675\" data-end=\"3742\"\u003e\n\u003ctd data-start=\"3675\" data-end=\"3695\" data-col-size=\"sm\"\u003eCNS sleep network\u003c\/td\u003e\n\u003ctd data-start=\"3695\" data-end=\"3719\" data-col-size=\"md\"\u003e↑ SWS and GH coupling\u003c\/td\u003e\n\u003ctd data-start=\"3719\" data-end=\"3742\" data-col-size=\"sm\"\u003eHypothalamus\/cortex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3744\" data-end=\"3747\"\u003e\n\u003ch2 data-start=\"3749\" data-end=\"3771\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3773\" data-end=\"4356\"\u003e\n\u003cli data-start=\"3773\" data-end=\"3856\"\u003e\n\u003cp data-start=\"3775\" data-end=\"3856\"\u003e\u003cstrong data-start=\"3775\" data-end=\"3790\"\u003eAbsorption:\u003c\/strong\u003e Effective by \u003cstrong data-start=\"3804\" data-end=\"3820\"\u003eSC injection\u003c\/strong\u003e; albumin coupling occurs in vivo.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3857\" data-end=\"3998\"\u003e\n\u003cp data-start=\"3859\" data-end=\"3998\"\u003e\u003cstrong data-start=\"3859\" data-end=\"3873\"\u003eHalf-life:\u003c\/strong\u003e Apparent \u003cstrong data-start=\"3883\" data-end=\"3899\"\u003et½ ~5–8 days\u003c\/strong\u003e with \u003cstrong data-start=\"3905\" data-end=\"3946\"\u003eIGF-1 elevation persisting ~1–2 weeks\u003c\/strong\u003e after a dose (formulation- and cohort-dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3999\" data-end=\"4111\"\u003e\n\u003cp data-start=\"4001\" data-end=\"4111\"\u003e\u003cstrong data-start=\"4001\" data-end=\"4018\"\u003eDistribution:\u003c\/strong\u003e \u003cstrong data-start=\"4019\" data-end=\"4045\"\u003eAlbumin-bound fraction\u003c\/strong\u003e predominates, limiting renal filtration and extending exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4112\" data-end=\"4204\"\u003e\n\u003cp data-start=\"4114\" data-end=\"4204\"\u003e\u003cstrong data-start=\"4114\" data-end=\"4128\"\u003eClearance:\u003c\/strong\u003e Proteolysis of peptide–albumin complex; \u003cstrong data-start=\"4169\" data-end=\"4179\"\u003eno CYP\u003c\/strong\u003e interactions expected.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4205\" data-end=\"4356\"\u003e\n\u003cp data-start=\"4207\" data-end=\"4356\"\u003e\u003cstrong data-start=\"4207\" data-end=\"4245\"\u003eDosing paradigm (investigational):\u003c\/strong\u003e \u003cstrong data-start=\"4246\" data-end=\"4273\"\u003eWeekly to twice-monthly\u003c\/strong\u003e schedules in early studies to maintain IGF-1 within the age-adjusted normal range.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4358\" data-end=\"4361\"\u003e\n\u003ch2 data-start=\"4363\" data-end=\"4408\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4410\" data-end=\"4447\"\u003e4.1 Healthy \u0026amp; Overweight Adults\u003c\/h3\u003e\n\u003cp data-start=\"4448\" data-end=\"4655\"\u003eSingle and multiple ascending-dose studies demonstrated \u003cstrong data-start=\"4504\" data-end=\"4546\"\u003esignificant, sustained IGF-1 increases\u003c\/strong\u003e with acceptable short-term tolerability and a \u003cstrong data-start=\"4593\" data-end=\"4620\"\u003elow injection frequency\u003c\/strong\u003e compared with daily secretagogues.\u003c\/p\u003e\n\u003ch3 data-start=\"4657\" data-end=\"4697\"\u003e4.2 Growth-Hormone Axis Phenotypes\u003c\/h3\u003e\n\u003cp data-start=\"4698\" data-end=\"4889\"\u003eIn adults with \u003cstrong data-start=\"4713\" data-end=\"4744\"\u003efunctional GH insufficiency\u003c\/strong\u003e features (central adiposity, low-normal IGF-1), pilot work shows \u003cstrong data-start=\"4810\" data-end=\"4861\"\u003efavorable endocrine and body-composition trends\u003c\/strong\u003e—pivotal trials are lacking.\u003c\/p\u003e\n\u003ch3 data-start=\"4891\" data-end=\"4923\"\u003e4.3 Sleep \u0026amp; Neurocognition\u003c\/h3\u003e\n\u003cp data-start=\"4924\" data-end=\"5116\"\u003eIn midlife cohorts, \u003cstrong data-start=\"4944\" data-end=\"4964\"\u003eSWS augmentation\u003c\/strong\u003e and modest improvements in \u003cstrong data-start=\"4992\" data-end=\"5014\"\u003eexecutive function\u003c\/strong\u003e have been observed with GHRH-based regimens; CJC-DAC data are limited but mechanistically concordant.\u003c\/p\u003e\n\u003ch3 data-start=\"5118\" data-end=\"5151\"\u003e4.4 Metabolic Liver Disease\u003c\/h3\u003e\n\u003cp data-start=\"5152\" data-end=\"5295\"\u003ePrograms are exploring \u003cstrong data-start=\"5175\" data-end=\"5189\"\u003eNAFLD\/MASH\u003c\/strong\u003e endpoints (MRI-PDFF, ALT\/AST) based on GH-axis biology; confirmatory randomized evidence is still needed.\u003c\/p\u003e\n\u003chr data-start=\"5297\" data-end=\"5300\"\u003e\n\u003ch2 data-start=\"5302\" data-end=\"5335\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5337\" data-end=\"5816\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5337\" data-end=\"5375\"\u003e\n\u003ctr data-start=\"5337\" data-end=\"5375\"\u003e\n\u003cth data-start=\"5337\" data-end=\"5345\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5345\" data-end=\"5357\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5357\" data-end=\"5375\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5390\" data-end=\"5816\"\u003e\n\u003ctr data-start=\"5390\" data-end=\"5500\"\u003e\n\u003ctd data-start=\"5390\" data-end=\"5415\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5392\" data-end=\"5414\"\u003eSarcopenic obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5415\" data-end=\"5479\" data-col-size=\"md\"\u003eLong-acting physiologic GH pulses to reshape body composition\u003c\/td\u003e\n\u003ctd data-start=\"5479\" data-end=\"5500\" data-col-size=\"sm\"\u003eEarly feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5501\" data-end=\"5592\"\u003e\n\u003ctd data-start=\"5501\" data-end=\"5518\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5503\" data-end=\"5517\"\u003eNAFLD\/MASH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5518\" data-end=\"5575\" data-col-size=\"md\"\u003eVisceral-fat reduction + hepatic lipid flux modulation\u003c\/td\u003e\n\u003ctd data-start=\"5575\" data-end=\"5592\" data-col-size=\"sm\"\u003ePilot designs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5593\" data-end=\"5692\"\u003e\n\u003ctd data-start=\"5593\" data-end=\"5617\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5595\" data-end=\"5616\"\u003eSleep\/SWS decline\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5617\" data-end=\"5672\" data-col-size=\"md\"\u003eRestore nocturnal GH coupling with infrequent dosing\u003c\/td\u003e\n\u003ctd data-start=\"5672\" data-end=\"5692\" data-col-size=\"sm\"\u003eProof-of-concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5693\" data-end=\"5816\"\u003e\n\u003ctd data-start=\"5693\" data-end=\"5724\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5695\" data-end=\"5723\"\u003eEndocrine rehabilitation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5724\" data-end=\"5801\" data-col-size=\"md\"\u003eAdjunct in hypothalamic suppression states (post-stress, critical illness)\u003c\/td\u003e\n\u003ctd data-start=\"5801\" data-end=\"5816\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5818\" data-end=\"5821\"\u003e\n\u003ch2 data-start=\"5823\" data-end=\"5852\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5854\" data-end=\"6523\"\u003e\n\u003cli data-start=\"5854\" data-end=\"6012\"\u003e\n\u003cp data-start=\"5856\" data-end=\"6012\"\u003e\u003cstrong data-start=\"5856\" data-end=\"5867\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-start=\"5868\" data-end=\"5896\"\u003eInjection-site reactions\u003c\/strong\u003e, \u003cstrong data-start=\"5898\" data-end=\"5907\"\u003eedema\u003c\/strong\u003e, \u003cstrong data-start=\"5909\" data-end=\"5931\"\u003earthralgia\/myalgia\u003c\/strong\u003e, \u003cstrong data-start=\"5933\" data-end=\"5976\"\u003eparesthesia\/carpal-tunnel-like symptoms\u003c\/strong\u003e (fluid retention) as IGF-1 rises.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6013\" data-end=\"6113\"\u003e\n\u003cp data-start=\"6015\" data-end=\"6113\"\u003e\u003cstrong data-start=\"6015\" data-end=\"6029\"\u003eMetabolic:\u003c\/strong\u003e \u003cstrong data-start=\"6030\" data-end=\"6053\"\u003eGlucose intolerance\u003c\/strong\u003e can emerge in predisposed patients—monitor \u003cstrong data-start=\"6097\" data-end=\"6110\"\u003eFPG\/HbA1c\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6114\" data-end=\"6235\"\u003e\n\u003cp data-start=\"6116\" data-end=\"6235\"\u003e\u003cstrong data-start=\"6116\" data-end=\"6130\"\u003eEndocrine:\u003c\/strong\u003e Target \u003cstrong data-start=\"6138\" data-end=\"6171\"\u003eIGF-1 within age-normal range\u003c\/strong\u003e; excessive, sustained elevation increases adverse-event risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6236\" data-end=\"6342\"\u003e\n\u003cp data-start=\"6238\" data-end=\"6342\"\u003e\u003cstrong data-start=\"6238\" data-end=\"6261\"\u003eRare\/observational:\u003c\/strong\u003e \u003cstrong data-start=\"6262\" data-end=\"6288\"\u003eInjection-site nodules\u003c\/strong\u003e (albumin binding), transient \u003cstrong data-start=\"6318\" data-end=\"6339\"\u003eheadache\/flushing\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6343\" data-end=\"6523\"\u003e\n\u003cp data-start=\"6345\" data-end=\"6523\"\u003e\u003cstrong data-start=\"6345\" data-end=\"6366\"\u003eOncology caution:\u003c\/strong\u003e As with any GH\/IGF-1–elevating therapy, theoretical \u003cstrong data-start=\"6419\" data-end=\"6437\"\u003emitogenic risk\u003c\/strong\u003e warrants avoidance in \u003cstrong data-start=\"6460\" data-end=\"6481\"\u003eactive malignancy\u003c\/strong\u003e and vigilance in those with prior cancer.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6525\" data-end=\"6554\"\u003e\u003cstrong data-start=\"6525\" data-end=\"6554\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6556\" data-end=\"7030\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6556\" data-end=\"6653\"\u003e\n\u003ctr data-start=\"6556\" data-end=\"6653\"\u003e\n\u003cth data-start=\"6556\" data-end=\"6566\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"6566\" data-end=\"6590\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6568\" data-end=\"6589\"\u003eCJC-1295 with DAC\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6590\" data-end=\"6619\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6592\" data-end=\"6618\"\u003eSermorelin (GHRH 1–29)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6619\" data-end=\"6653\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6621\" data-end=\"6651\"\u003eMK-677 (oral GHSR agonist)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6672\" data-end=\"7030\"\u003e\n\u003ctr data-start=\"6672\" data-end=\"6738\"\u003e\n\u003ctd data-start=\"6672\" data-end=\"6688\" data-col-size=\"sm\"\u003eDosing burden\u003c\/td\u003e\n\u003ctd data-start=\"6688\" data-end=\"6711\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6690\" data-end=\"6710\"\u003eWeekly–bi-weekly\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6711\" data-end=\"6724\" data-col-size=\"sm\"\u003eNightly SC\u003c\/td\u003e\n\u003ctd data-start=\"6724\" data-end=\"6738\" data-col-size=\"sm\"\u003eDaily oral\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6739\" data-end=\"6850\"\u003e\n\u003ctd data-start=\"6739\" data-end=\"6755\" data-col-size=\"sm\"\u003eIGF-1 profile\u003c\/td\u003e\n\u003ctd data-start=\"6755\" data-end=\"6804\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6757\" data-end=\"6803\"\u003eSustained, physiologic-range (if titrated)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6804\" data-end=\"6825\" data-col-size=\"sm\"\u003eTransient, smaller\u003c\/td\u003e\n\u003ctd data-start=\"6825\" data-end=\"6850\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6827\" data-end=\"6848\"\u003eSustained, higher\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6851\" data-end=\"6909\"\u003e\n\u003ctd data-start=\"6851\" data-end=\"6869\" data-col-size=\"sm\"\u003eAppetite effect\u003c\/td\u003e\n\u003ctd data-start=\"6869\" data-end=\"6879\" data-col-size=\"md\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-start=\"6879\" data-end=\"6889\" data-col-size=\"sm\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-start=\"6889\" data-end=\"6909\" data-col-size=\"sm\"\u003e↑ (ghrelin-like)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6910\" data-end=\"6969\"\u003e\n\u003ctd data-start=\"6910\" data-end=\"6927\" data-col-size=\"sm\"\u003eEdema\/CTS risk\u003c\/td\u003e\n\u003ctd data-start=\"6927\" data-end=\"6942\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6929\" data-end=\"6941\"\u003eModerate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6942\" data-end=\"6957\" data-col-size=\"sm\"\u003eLow–moderate\u003c\/td\u003e\n\u003ctd data-start=\"6957\" data-end=\"6969\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6970\" data-end=\"7030\"\u003e\n\u003ctd data-start=\"6970\" data-end=\"6988\" data-col-size=\"sm\"\u003eGlycaemic drift\u003c\/td\u003e\n\u003ctd data-start=\"6988\" data-end=\"7003\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6990\" data-end=\"7002\"\u003ePossible\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7003\" data-end=\"7014\" data-col-size=\"sm\"\u003eLow–mild\u003c\/td\u003e\n\u003ctd data-start=\"7014\" data-end=\"7030\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7016\" data-end=\"7028\"\u003eModerate\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7032\" data-end=\"7035\"\u003e\n\u003ch2 data-start=\"7037\" data-end=\"7063\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7065\" data-end=\"7327\"\u003e\n\u003cli data-start=\"7065\" data-end=\"7130\"\u003e\n\u003cp data-start=\"7067\" data-end=\"7130\"\u003e\u003cstrong data-start=\"7067\" data-end=\"7081\"\u003eApprovals:\u003c\/strong\u003e \u003cstrong data-start=\"7082\" data-end=\"7090\"\u003eNone\u003c\/strong\u003e for therapeutic use in major markets.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7131\" data-end=\"7255\"\u003e\n\u003cp data-start=\"7133\" data-end=\"7255\"\u003e\u003cstrong data-start=\"7133\" data-end=\"7150\"\u003eAvailability:\u003c\/strong\u003e Research\/compounded channels in some regions; \u003cstrong data-start=\"7197\" data-end=\"7227\"\u003equality\/purity not assured\u003c\/strong\u003e outside regulated trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7256\" data-end=\"7327\"\u003e\n\u003cp data-start=\"7258\" data-end=\"7327\"\u003e\u003cstrong data-start=\"7258\" data-end=\"7268\"\u003eSport:\u003c\/strong\u003e Agents that \u003cstrong data-start=\"7281\" data-end=\"7302\"\u003eincrease GH\/IGF-1\u003c\/strong\u003e are \u003cstrong data-start=\"7307\" data-end=\"7326\"\u003eWADA-prohibited\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7329\" data-end=\"7332\"\u003e\n\u003ch2 data-start=\"7334\" data-end=\"7357\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7359\" data-end=\"7849\"\u003e\n\u003cli data-start=\"7359\" data-end=\"7476\"\u003e\n\u003cp data-start=\"7361\" data-end=\"7476\"\u003e\u003cstrong data-start=\"7361\" data-end=\"7380\"\u003eControlled RCTs\u003c\/strong\u003e in \u003cstrong data-start=\"7384\" data-end=\"7406\"\u003esarcopenic obesity\u003c\/strong\u003e and \u003cstrong data-start=\"7411\" data-end=\"7425\"\u003eNAFLD\/MASH\u003c\/strong\u003e with imaging (MRI-PDFF) and metabolic endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7477\" data-end=\"7591\"\u003e\n\u003cp data-start=\"7479\" data-end=\"7591\"\u003e\u003cstrong data-start=\"7479\" data-end=\"7505\"\u003eIGF-1-guided titration\u003c\/strong\u003e strategies to balance efficacy and safety while avoiding supraphysiologic exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7592\" data-end=\"7723\"\u003e\n\u003cp data-start=\"7594\" data-end=\"7723\"\u003e\u003cstrong data-start=\"7594\" data-end=\"7618\"\u003eCombination regimens\u003c\/strong\u003e with \u003cstrong data-start=\"7624\" data-end=\"7636\"\u003eexercise\u003c\/strong\u003e, \u003cstrong data-start=\"7638\" data-end=\"7651\"\u003enutrition\u003c\/strong\u003e, or \u003cstrong data-start=\"7656\" data-end=\"7684\"\u003eincretin-based therapies\u003c\/strong\u003e to enhance cardiometabolic outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7724\" data-end=\"7849\"\u003e\n\u003cp data-start=\"7726\" data-end=\"7849\"\u003e\u003cstrong data-start=\"7726\" data-end=\"7754\"\u003eFormulation optimization\u003c\/strong\u003e (stability, injection volume) and \u003cstrong data-start=\"7789\" data-end=\"7813\"\u003ereal-world adherence\u003c\/strong\u003e studies versus daily secretagogues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7851\" data-end=\"7854\"\u003e\n\u003ch3 data-start=\"7856\" data-end=\"7879\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"7881\" data-end=\"8805\"\u003e\n\u003cli data-start=\"7881\" data-end=\"8038\"\u003e\n\u003cp data-start=\"7883\" data-end=\"8038\"\u003eTeichman S.L. et al. \u003cstrong data-start=\"7904\" data-end=\"7986\"\u003eCJC-1295, a long-acting GHRH analog, increases GH and IGF-1 in healthy adults.\u003c\/strong\u003e\u003cem data-start=\"7987\" data-end=\"8035\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8039\" data-end=\"8160\"\u003e\n\u003cp data-start=\"8041\" data-end=\"8160\"\u003eIonescu M. et al. \u003cstrong data-start=\"8059\" data-end=\"8132\"\u003ePharmacokinetics and pharmacodynamics of DAC-conjugated GHRH analogs.\u003c\/strong\u003e \u003cem data-start=\"8133\" data-end=\"8157\"\u003eClinical Endocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8161\" data-end=\"8261\"\u003e\n\u003cp data-start=\"8163\" data-end=\"8261\"\u003eVeldhuis J.D., Iranmanesh A. \u003cstrong data-start=\"8192\" data-end=\"8238\"\u003ePhysiology of GH pulsatility and feedback.\u003c\/strong\u003e \u003cem data-start=\"8239\" data-end=\"8258\"\u003eEndocrine Reviews\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8262\" data-end=\"8369\"\u003e\n\u003cp data-start=\"8264\" data-end=\"8369\"\u003eJohannsson G. et al. \u003cstrong data-start=\"8285\" data-end=\"8348\"\u003eBody composition and lipid changes with GH-axis modulation.\u003c\/strong\u003e \u003cem data-start=\"8349\" data-end=\"8358\"\u003eObesity\u003c\/em\u003e; \u003cem data-start=\"8360\" data-end=\"8366\"\u003eJCEM\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8370\" data-end=\"8466\"\u003e\n\u003cp data-start=\"8372\" data-end=\"8466\"\u003eVan Cauter E., Born J. \u003cstrong data-start=\"8395\" data-end=\"8433\"\u003eGHRH and sleep\/somnogenic effects.\u003c\/strong\u003e \u003cem data-start=\"8434\" data-end=\"8441\"\u003eSleep\u003c\/em\u003e; \u003cem data-start=\"8443\" data-end=\"8463\"\u003eNeuroendocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8467\" data-end=\"8535\"\u003e\n\u003cp data-start=\"8469\" data-end=\"8535\"\u003eClemmons D.R. \u003cstrong data-start=\"8483\" data-end=\"8525\"\u003eIGF-1 biology and clinical monitoring.\u003c\/strong\u003e \u003cem data-start=\"8526\" data-end=\"8532\"\u003eJCEM\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8536\" data-end=\"8640\"\u003e\n\u003cp data-start=\"8538\" data-end=\"8640\"\u003eChalasani N. et al. \u003cstrong data-start=\"8558\" data-end=\"8601\"\u003eNAFLD endpoints and MRI-PDFF in trials.\u003c\/strong\u003e \u003cem data-start=\"8602\" data-end=\"8614\"\u003eHepatology\u003c\/em\u003e; \u003cem data-start=\"8616\" data-end=\"8637\"\u003eLiver International\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8641\" data-end=\"8733\"\u003e\n\u003cp data-start=\"8643\" data-end=\"8733\"\u003eFukuoka H. et al. \u003cstrong data-start=\"8661\" data-end=\"8709\"\u003eSecretagogue synergy (GHRH + GHSR agonists).\u003c\/strong\u003e \u003cem data-start=\"8710\" data-end=\"8730\"\u003eNeuroendocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8734\" data-end=\"8805\"\u003e\n\u003cp data-start=\"8736\" data-end=\"8805\"\u003eWADA. \u003cstrong data-start=\"8742\" data-end=\"8805\"\u003eProhibited List 2025 — peptide hormones and growth factors.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684853739858,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/CJC-1295_with_dac_10mg.png?v=1770834866","url":"https:\/\/sciencepeptideslab.com\/products\/cjc-1295-with-dac-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}